INS and cancer: In this sensitivity analysis, we detected an increased adjusted HR for type 2 diabetes requiring insulin treatment in the cancer group (except pancreatic cancer), compared with the non-cancer group (adjusted HR, 1.35; 95% CI, 1.07–1.69).